Article Text

Download PDFPDF

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
  1. R Fleischmann1,
  2. J Vencovsky2,
  3. R F van Vollenhoven3,
  4. D Borenstein4,
  5. J Box5,
  6. G Coteur6,
  7. N Goel7,
  8. H-P Brezinschek8,
  9. A Innes9,
  10. V Strand10
  1. 1
    University of Texas Southwestern Medical Center, Dallas, Texas, USA
  2. 2
    Institute of Rheumatology, Prague, Czech Republic
  3. 3
    Karolinska Institute, Stockholm, Sweden
  4. 4
    George Washington University Medical Center, Washington, DC, USA
  5. 5
    Carolina Bone and Joint, Charlotte, North Carolina, USA
  6. 6
    UCB, Braine l’Alleud, Belgium
  7. 7
    UCB, Atlanta, Georgia, USA
  8. 8
    Medical University Graz, Graz, Austria
  9. 9
    UCB, Slough, UK
  10. 10
    Stanford University, Stanford, California, USA
  1. R Fleischmann, University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd., Dallas, Texas 75235, USA; rfleischmann{at}arthdocs.com

Footnotes

  • Competing interests: JV has received a fee from UCB for speaking at a National Congress; RFvV has received consulting fees from UCB; DB has received reimbursement from UCB for attending a symposium and funds for research; JB has received reimbursement from UCB for attending a symposium and funds for research; GC is a full time employee of and holds stocks in UCB; AI is a full time employee at UCB and has shares in the company; NG is a full time employee of UCB and has shares and stock options in the company; VS has worked as an independent biopharmaceutical consultant in clinical development and regulatory affairs since September 1991 and is currently a consultant to various companies, but has not and does not now hold stock in any company. RF has received consulting fees and funds for clinical research from UCB.

  • Funding: The FAST4WARD study was funded by UCB. UCB contributed to the design, conduct and reporting of the study.

  • Ethics approval: Institutional review boards or ethics committees approved the protocol at each centre. All patients gave written consent, and the study was conducted in accordance with the Declaration of Helsinki.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: JV has received a fee from UCB for speaking at a National Congress; RFvV has received consulting fees from UCB; DB has received reimbursement from UCB for attending a symposium and funds for research; JB has received reimbursement from UCB for attending a symposium and funds for research; GC is a full time employee of and holds stocks in UCB; AI is a full time employee at UCB and has shares in the company; NG is a full time employee of UCB and has shares and stock options in the company; VS has worked as an independent biopharmaceutical consultant in clinical development and regulatory affairs since September 1991 and is currently a consultant to various companies, but has not and does not now hold stock in any company. RF has received consulting fees and funds for clinical research from UCB.

  • Funding: The FAST4WARD study was funded by UCB. UCB contributed to the design, conduct and reporting of the study.

  • Ethics approval: Institutional review boards or ethics committees approved the protocol at each centre. All patients gave written consent, and the study was conducted in accordance with the Declaration of Helsinki.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles